4-甲基环己基肼 | 158438-47-2

• 分子结构分类: 有机化合物 - 有机氮化合物
• 中文名称: 4-甲基环己基肼
• 英文名称: (4-Methylcyclohexyl)hydrazine
• CAS: 158438-47-2
• 化学式: C₇H₁₆N₂
• 分子量: 128.217
• InChiKey: APRAKIKVYGWZQG-UHFFFAOYSA-N

物化性质

• 沸点：
  219.5±7.0 °C(Predicted)
• 密度：
  0.92±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.1
• 重原子数：
  9
• 可旋转键数：
  1
• 环数：
  1.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  38
• 氢给体数：
  2
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  、 4-甲基环己基肼 在 溶剂黄146 作用下， 反应 2.0h， 生成
  参考文献：
  名称：

  Triazolo and imidazo dihydropyrazolopyrimidine potassium channel antagonists

  摘要：

  Previously disclosed C6 amido and benzimidazole dihydropyrazolopyrimidines were potent and selective blockers of I-Kur current. Syntheses and SAR for C6 triazolo and imidazo dihydropyrazolopyrimidines series are described. Trifluoromethylcyclohexyl N(1) triazole, compound 51, was identified as a potent and selective K(v)1.5 inhibitor with an acceptable PK and liability profile. (C) 2013 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2013.01.064

文献信息

• GLI1 INHIBITORS AND USES THEREOF
  申请人：Leadiant Biosciences SA

  公开号：EP3388419A1

  公开（公告）日：2018-10-17

  The present invention relates to compounds able to inhibit the protein Gli1 having the formula wherein the meanings of the substituents are indicated in the description, for use in the treatment of diseases related to Gli-1. The present invention also relates to compounds of formula (IIa) and (IIb) and to their use as medicaments, in particular for the treatment of diseases related to Gli1, more in particular for the treatment of tumors. Pharmaceutical compositions comprising said compounds of formula (IIa) or (IIb) are also within the scope of the present invention.

  本发明涉及一种能够抑制蛋白质Gli1的化合物，其具有下述式子，其中取代基的含义在说明中指明，用于治疗与Gli-1相关的疾病。本发明还涉及具有式子(IIa)和(IIb)的化合物及其作为药物的用途，特别用于治疗与Gli1相关的疾病，更具体地用于肿瘤的治疗。包含上述式子(IIa)或(IIb)的药物组合物也属于本发明的范围内。
• [EN] SUBSTITUTED PYRAZOLES AS p38 KINASE INHIBITORS<br/>[FR] PYRAZOLES SUBSTITUES UTILISES COMME INHIBITEURS DE LA KINASE p38
  申请人：SEARLE & CO

  公开号：WO2000031063A1

  公开（公告）日：2000-06-02

  A class of pyrazole derivatives is described for use in treating p38 kinase mediated disorders. Compounds of particular interest are defined by Formula (IA), wherein R?1, R2, R3 and R4¿ are as described in the specification.

  本文描述了一类吡唑衍生物，用于治疗p38激酶介导的疾病。 特别感兴趣的化合物由公式（IA）定义，其中R?1，R2，R3和R4¿如规范中所述。
• SUBSTITUED PYRAZOLES AS P38 KINASE INHIBITORS
  申请人：G.D. SEARLE & CO.

  公开号：EP1144403A1

  公开（公告）日：2001-10-17
• [EN] IMPROVED PROSTATE-SPECIFIC MEMBRANE ANTIGEN TARGETING RADIOPHARMACEUTICALS AND USES THEREOF<br/>[FR] PRODUITS RADIOPHARMACEUTIQUES CIBLANT L'ANTIGÈNE MEMBRANAIRE SPÉCIFIQUE DE LA PROSTATE AMÉLIORÉS ET LEURS UTILISATIONS
  申请人：[en]UNIVERSITÄT HEIDELBERG

  公开号：WO2022253785A2

  公开（公告）日：2022-12-08

  The present invention relates to diagnosis and treatment of malignancies characterised by prostate-specific membrane antigen (PSMA) expression. The invention particularly relates to improved radiopharmaceuticals which selectively bind to PSMA and are suitable for planar imaging of PSMA expression in subjects to diagnose and/or monitor malignancies wherein PSMA is (over)expressed. Additionally, the invention relates to improved radiopharmaceuticals which selectively bind to PSMA and are suitable to act as radionuclide treatment agents. The radiopharmaceuticals rely on a pharmacophore capable of interacting with PSMA and N-terminal mercaptoacetyltripeptides capable of coordinating radioactive metals such as technetium and rhenium.